Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Exclusion Criteria

• •1. Decompensated hepatic cirrhosis or MELD score \> 13 (ages 12 to \<18) or PELD score \> 13 (ages 3 to \< 12).
• •2. Modified Nazer score \> 7.
• •3. Clinically significant gastrointestinal bleed within past 3 months.
• •4. Alanine aminotransferase (ALT) \> 2 × upper limit of normal (ULN) for participants treated for \> 28 days with WD therapy or ALT \> 5 × ULN for treatment-naïve participants or participants who have been treated for ≤ 28 days.
• •5. Marked neurological disease requiring either nasogastric feeding tube or intensive inpatient medical care.
• •6. Hemoglobin less than lower limit of the reference range for age and sex.
• •7. History of seizure activity within 6 months prior to informed consent/assent.
• •8. Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease stage 5) or estimated glomerular filtration rate \< 30 milliliters/minute/1.73 meter squared.